A Glimpse of What to Expect
Dedicated to the Delivery of Safe, Effective and Commercially Viable CAR and TCR Immunotherapies for Liquid and Solid Tumours
Join the top minds from large pharma, biotech and academia who are striving to harmonise the European regulatory process, streamline manufacturing and optimise CAR-T targets and constructs for solid tumours.
Click here to download the preliminary agenda. Pre-launch pricing expires on the 18th of October! Don't miss out!
Proud to Partner With